neoplasm staging

Summary

Summary: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.

Top Publications

  1. pmc Final version of 2009 AJCC melanoma staging and classification
    Charles M Balch
    Department of Surgery, Oncology and Dermatology, Johns Hopkins Medical Institutions, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA
    J Clin Oncol 27:6199-206. 2009
  2. ncbi Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    Jerome Galon
    INSERM U 255, Paris, 75006 France Université Paris Descartes Paris 5, Faculte de Medecine, Paris, 75006 France
    Science 313:1960-4. 2006
  3. ncbi Preoperative versus postoperative chemoradiotherapy for rectal cancer
    Rolf Sauer
    Department of Radiation Therapy, University of Erlangen, Erlangen, Germany
    N Engl J Med 351:1731-40. 2004
  4. doi Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma
    Charles H Lawrie
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 141:672-5. 2008
  5. doi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
  6. doi Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
  7. ncbi The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours
    Peter Goldstraw
    Royal Brompton Hospital, Imperial College, London, United Kingdom
    J Thorac Oncol 2:706-14. 2007
  8. doi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
  9. ncbi Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Mass 02215, USA
    JAMA 280:969-74. 1998
  10. ncbi Esophageal cancer
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 349:2241-52. 2003

Research Grants

  1. REGULATION OF PROSTATE CANCER PROGRAMMED CELL DEATH
    Andrew Kraft; Fiscal Year: 2001
  2. A Genetic Screening Policy Model for Colorectal Cancer
    Scott Ramsey; Fiscal Year: 2006
  3. Clinical Significance of Apoptosis in Colon Cancer
    Frank Sinicrope; Fiscal Year: 2006
  4. Aberrant Crypt Foci as a Biomarker for Chemoprevention
    Frank Sinicrope; Fiscal Year: 2009
  5. Aberrant Crypt Foci as a Biomarker for Chemoprevention
    Frank Sinicrope; Fiscal Year: 2007
  6. A Novel Breast Cancer Biomarker
    Dennis Sgroi; Fiscal Year: 2009
  7. Polyphenon E for the Chemoprevention of Colorectal Cancer
    Frank A Sinicrope; Fiscal Year: 2010
  8. A Novel Breast Cancer Biomarker
    Dennis C Sgroi; Fiscal Year: 2010
  9. Timing of Rectal Cancer Response to Chemoradiation
    Julio Garcia Aguilar; Fiscal Year: 2009
  10. Mechanisms of Carcinogenesis in Biliary Epithelia
    Gregory Gores; Fiscal Year: 2005

Detail Information

Publications289 found, 100 shown here

  1. pmc Final version of 2009 AJCC melanoma staging and classification
    Charles M Balch
    Department of Surgery, Oncology and Dermatology, Johns Hopkins Medical Institutions, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA
    J Clin Oncol 27:6199-206. 2009
    ..To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database...
  2. ncbi Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    Jerome Galon
    INSERM U 255, Paris, 75006 France Université Paris Descartes Paris 5, Faculte de Medecine, Paris, 75006 France
    Science 313:1960-4. 2006
    ..In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies...
  3. ncbi Preoperative versus postoperative chemoradiotherapy for rectal cancer
    Rolf Sauer
    Department of Radiation Therapy, University of Erlangen, Erlangen, Germany
    N Engl J Med 351:1731-40. 2004
    ..In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer...
  4. doi Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma
    Charles H Lawrie
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 141:672-5. 2008
    ..05). This is the first description of circulating microRNAs and suggests that microRNAs have potential as non-invasive diagnostic markers for DLBCL and possibly other cancers...
  5. doi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  6. doi Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
    ..These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC...
  7. ncbi The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours
    Peter Goldstraw
    Royal Brompton Hospital, Imperial College, London, United Kingdom
    J Thorac Oncol 2:706-14. 2007
    ..The recommendations of this committee for changes to the T, N, and M descriptors have been published. This report contains the proposals for the new stage groupings...
  8. doi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  9. ncbi Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Mass 02215, USA
    JAMA 280:969-74. 1998
    ..Interstitial radiation (implant) therapy is used to treat clinically localized adenocarcinoma of the prostate, but how it compares with other treatments is not known...
  10. ncbi Esophageal cancer
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 349:2241-52. 2003
  11. ncbi Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
    C M Balch
    Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 19:3622-34. 2001
    ..Thirteen cancer centers and cancer cooperative groups contributed staging and survival data from a total of 30,450 melanoma patients from their databases in order to validate this staging proposal...
  12. ncbi Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
    Shinichi Sakuramoto
    Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
    N Engl J Med 357:1810-20. 2007
    ..Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer...
  13. ncbi Prognostic and predictive factors in breast cancer by immunohistochemical analysis
    D C Allred
    Department of Pathology, University of Texas Health Science Center, San Antonio 78284, USA
    Mod Pathol 11:155-68. 1998
    ..In the future, these and other factors will be incorporated into a prognostic index that will better reflect the biologic diversity of breast cancer and that will more accurately predict clinical outcome...
  14. pmc Stereotactic body radiation therapy for inoperable early stage lung cancer
    Robert Timmerman
    Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    JAMA 303:1070-6. 2010
    ..Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor control (30%-40%) and a high rate of mortality (3-year survival, 20%-35%) with current management...
  15. ncbi Effector memory T cells, early metastasis, and survival in colorectal cancer
    Franck Pages
    INSERM UNITE 255, René Descartes Faculté de Médecine, Assistance Publique Hopitaux de Paris, Cordeliers Biomedical Research Center, University Paris 6, Paris, France
    N Engl J Med 353:2654-66. 2005
    ..The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown...
  16. ncbi Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells
    Li Bing Song
    State Key Laboratory of Oncology in Southern China, Sun Yat sen University Cancer Center, Guangzhou, China
    Cancer Res 66:6225-32. 2006
    ....
  17. ncbi Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
    Robert F Ozols
    Medical Science Department, Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 21:3194-200. 2003
    ..Thus, we conducted a noninferiority trial of cisplatin and paclitaxel versus carboplatin and paclitaxel in this population...
  18. doi Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    Tudor Ciuleanu
    Oncological Institute Ion Chiricuta, Cluj, Romania
    Lancet 374:1432-40. 2009
    ..We assessed pemetrexed as maintenance therapy in patients with this disease...
  19. doi MicroRNA signature predicts survival and relapse in lung cancer
    Sung Liang Yu
    Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan 100, Republic of China
    Cancer Cell 13:48-57. 2008
    ..This microRNA signature is an independent predictor of the cancer relapse and survival of NSCLC patients...
  20. ncbi Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
    Robert E Bristow
    Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD 21287 1248, USA
    J Clin Oncol 20:1248-59. 2002
    ..To evaluate the relative effect of percent maximal cytoreductive surgery and other prognostic variables on survival among cohorts of patients with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy...
  21. ncbi Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Thierry Andre
    Hopital Tenon, Paris
    N Engl J Med 350:2343-51. 2004
    ..Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting...
  22. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases...
  23. pmc Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
    Julian R Molina
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:584-94. 2008
    ....
  24. ncbi Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Deborah K Armstrong
    Johns Hopkins Kimmel Cancer Center, Baltimore, USA
    N Engl J Med 354:34-43. 2006
    ..The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer...
  25. doi Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer
    Paul Salama
    School of Surgery and Biostatistics Unit, Cancer Trials, Western Australian Institute for Medical Research, University of Western Australia, Australia
    J Clin Oncol 27:186-92. 2009
    ..To determine the prognostic significance of FOXP3(+) lymphocyte (Treg) density in colorectal cancer compared with conventional histopathologic features and with CD8(+) and CD45RO(+) lymphocyte densities...
  26. pmc Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer
    J Joshua Smith
    Department of Surgery, Vanderbilt Medical Center, Nashville, TN, USA
    Gastroenterology 138:958-68. 2010
    ..We used a gene expression profile derived from invasive, murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify patients with colon cancer at risk of recurrence...
  27. ncbi Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
    E Y Woo
    Department of Surgery, Abramson Family Cancer Research Institute, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 61:4766-72. 2001
    ..These observations provide evidence for the contribution of regulatory T cells to immune dysfunction in cancer patients...
  28. ncbi Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Department of Oncology, De Boelelaan 1117, 1081 Amsterdam, The Netherlands
    J Clin Oncol 22:777-84. 2004
    ..Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability...
  29. doi Immune infiltration in human tumors: a prognostic factor that should not be ignored
    F Pages
    Inserm U872, Centre de Recherche des Cordeliers, Equipe 15, Paris, France
    Oncogene 29:1093-102. 2010
    ....
  30. ncbi International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005
    ..There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification...
  31. ncbi Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
    Arlene A Forastiere
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    N Engl J Med 349:2091-8. 2003
    ..The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown...
  32. ncbi Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging
    Jessica B O'Connell
    Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Ave, Rm 72 215 CHS, Los Angeles, CA 90095, USA
    J Natl Cancer Inst 96:1420-5. 2004
    ..Using nationally representative Surveillance, Epidemiology, and End Results (SEER) data, we compared survival rates associated with colon cancer stages defined according to both AJCC systems...
  33. ncbi Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 22:785-94. 2004
    ..This phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carboplatin in chemotherapy-naive patients with advanced NSCLC...
  34. ncbi Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System
    Jill S Barnholtz-Sloan
    Karmanos Cancer Institute, Wayne State University School of Medicine, 110 E Warren, Detroit, MI 48201, USA
    J Clin Oncol 22:2865-72. 2004
    ..The purpose of this study was to calculate population-based incidence proportions (IPs) of brain metastases from single primary lung, melanoma, breast, renal, or colorectal cancer...
  35. doi Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
    Peter C Fong
    Drug Development Unit, Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, UK
    J Clin Oncol 28:2512-9. 2010
    ..Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers...
  36. ncbi Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group
    David G Jayne
    Academic Unit of Surgery, St James s University Hospital, Leeds, United Kingdom
    J Clin Oncol 25:3061-8. 2007
    ..Few data are available on rectal cancer, and long-term data on survival and recurrence are now required...
  37. pmc The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report
    Susan L Cohn
    Department of Pediatrics, The University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 27:289-97. 2009
    ..The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification...
  38. pmc Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410
    Walter J Curran
    Department of Radiation Oncology and Winship Cancer Institute, Emory University, 1365C Clifton Rd, NE, Ste C4104, Atlanta, GA 30322, USA
    J Natl Cancer Inst 103:1452-60. 2011
    ..However, it is not known whether sequential or concurrent delivery of these therapies is the optimal combination strategy...
  39. pmc DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Natl Cancer Inst 103:863-75. 2011
    ..We determined the association of MMR status with colon cancer recurrence and examined the impact of 5-fluorouracil (FU)-based adjuvant therapy on recurrence variables...
  40. ncbi The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
    Lisa A Carey
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Clin Cancer Res 13:2329-34. 2007
    ..Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among these breast cancer subtypes...
  41. ncbi Increase of regulatory T cells in the peripheral blood of cancer patients
    Anna Maria Wolf
    Institute for Biomedical Aging Research, Austrian Academy of Sciences, 6020 Innsbruck, Austria
    Clin Cancer Res 9:606-12. 2003
    ..Experimental tumor models in mice revealed that Tregs are potent inhibitors of an antitumor immune response. The current study was designed to determine whether cancer patients exhibit an expanded Treg pool...
  42. ncbi Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer
    W T Creasman
    Int J Gynaecol Obstet 95:S105-43. 2006
  43. pmc CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115 USA
    Gut 58:90-6. 2009
    ..The independent effect of CIMP, MSI and BRAF mutation on prognosis remains uncertain...
  44. doi Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer
    Ramon Salazar
    Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Av Gran Vía 199 203, Barcelona, Spain 08907
    J Clin Oncol 29:17-24. 2011
    ..This study aims to develop a robust gene expression classifier that can predict disease relapse in patients with early-stage colorectal cancer (CRC)...
  45. ncbi Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma
    G Calais
    G Calais, Centre Hospitalier Universitaire Tours, France
    J Natl Cancer Inst 91:2081-6. 1999
    ..e., advanced oropharynx carcinoma)...
  46. ncbi Biomarkers in cancer staging, prognosis and treatment selection
    Joseph A Ludwig
    Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 5:845-56. 2005
    ..Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality...
  47. pmc Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases
    Charles M Balch
    Department of Surgery, Johns Hopkins Medical Institutions, 600 N Wolfe St, Osler 624, Baltimore, MD 21287, USA
    J Clin Oncol 28:2452-9. 2010
    ..To determine the survival rates and independent predictors of survival using a contemporary international cohort of patients with stage III melanoma...
  48. pmc TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
    G Rindi
    Dipartimento di Patologia e, Medicina di Laboratorio, Sezione di Anatomia Patologica, Universita di Parma, Via Gramsci, 14, 43100, Parma, Italy, and Department of Internal Medicine, Royal Free Hospital, London, UK
    Virchows Arch 449:395-401. 2006
    ..This proposal, which needs to be validated, is meant to help clinicians in the stratification, treatment, and follow-up of patients...
  49. doi Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials
    Giovanni Butturini
    Division of Surgery and Oncology, School of Cancer Studies, Royal Liverpool University Hospital, 5th Floor, UCD Bldg, Daulby St, Liverpool L69 3GA, England
    Arch Surg 143:75-83; discussion 83. 2008
    ..To assess the influence of resection margins and adjuvant chemoradiotherapy or chemotherapy on survival for patients with pancreatic cancer by meta-analysis of individual data from randomized controlled trials...
  50. ncbi Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer
    Anna V Ivshina
    Genome Institute of Singapore, Singapore
    Cancer Res 66:10292-301. 2006
    ....
  51. ncbi Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis
    Lonneke V van de Poll-Franse
    Comprehensive Cancer Centre South Eindhoven Cancer Registry, Eindhoven, The Netherlands
    Int J Cancer 120:1986-92. 2007
    ..In conclusion, diabetic cancer patients frequently were treated less aggressively and had a worse prognosis compared to those without diabetes...
  52. doi Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome
    Maria D Begnami
    Department of Pathology, Hospital A C Camargo, Rua Professor Antonio Prudente 211, Liberdade, Sa Paulo, Brazil
    J Clin Oncol 29:3030-6. 2011
    ..The effect of HER3 or HER4 expression in GC has not been sufficiently studied. In this study, we explored the gene and protein expression of the HER family in GC to establish new potential prognostic factors...
  53. doi Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, random
    Luis Paz-Ares
    Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocio, Seville, Spain
    Lancet Oncol 13:247-55. 2012
    ..The PARAMOUNT trial investigated whether continuation maintenance with pemetrexed improved progression-free survival after induction therapy with pemetrexed plus cisplatin...
  54. ncbi A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study
    Henry M Keys
    Department of Radiation Oncology, Albany Medical College, Albany, NY 12208, USA
    Gynecol Oncol 92:744-51. 2004
    ....
  55. doi Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study
    Achilles J Fakiris
    Department of Radiation Oncology, Indiana University School of Medicine, 535 Barnhill Drive, Indianapolis, IN 46202, USA
    Int J Radiat Oncol Biol Phys 75:677-82. 2009
    ..The 50-month results of a prospective Phase II trial of stereotactic body radiation therapy (SBRT) in medically inoperable patients are reported...
  56. pmc American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    Christopher G Azzoli
    American Society of Clinical Oncology, 2318 Mill Rd, Suite 800, Alexandria, VA 22314, USA
    J Clin Oncol 27:6251-66. 2009
    ..Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy...
  57. pmc Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
    Ahmed Ashour Ahmed
    Functional Genomics of Ovarian Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK
    J Pathol 221:49-56. 2010
    ..Because TP53 mutation is almost invariably present in HGPSC, it is not of substantial prognostic or predictive significance...
  58. pmc Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
    R A Kyle
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:3-9. 2009
    ..This paper provides the current criteria for diagnosis, staging, risk stratification and response assessment of MM...
  59. pmc Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
    M Reck
    Department of Thoracic Oncology, Krankenhaus Grosshansdorf, Grosshansdorf
    Ann Oncol 21:1804-9. 2010
    ..We report the final overall survival (OS) analysis from the phase III AVAiL trial...
  60. ncbi Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study
    Hiroshi Onishi
    Department of Radiology, School of Medicine, Yamanashi University, Shimokato, Chuo City, Yamanashi, Japan
    J Thorac Oncol 2:S94-100. 2007
    ..We retrospectively analyzed the treatment outcome of HypoFXSRT for stage I non-small cell lung cancer (NSCLC) treated in a Japanese multi-institutional study...
  61. ncbi Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients
    J P Stein
    Department of Urology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA
    J Clin Oncol 19:666-75. 2001
    ....
  62. ncbi Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases
    Ryosuke Tateishi
    Department of Gastroenterology, University of Tokyo, Tokyo, Japan
    Cancer 103:1201-9. 2005
    ..Previously reported treatment efficacy and complication rates have varied considerably...
  63. ncbi The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma
    Koji Hashimoto
    Department of Surgery, Fukuoka City Hospital, Fukuoka, Japan
    Cancer 103:1856-64. 2005
    ..The authors evaluated the significance of the preoperative serum C-reactive protein (CRP) level as a prognostic indicator in patients with hepatocellular carcinoma (HCC)...
  64. ncbi Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
    H von der Maase
    Aarhus University Hospital, Denmark
    J Clin Oncol 18:3068-77. 2000
    ..Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium...
  65. ncbi Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
    M J Piccart
    European Organization for Research and Treatment of Cancer EORTC Gynecological Cancer Cooperative Group, EORTC Data Center, Brussels, Belgium
    J Natl Cancer Inst 92:699-708. 2000
    ..Before considering the paclitaxel-cisplatin regimen as the new "standard," a group of European and Canadian investigators planned a confirmatory phase III trial...
  66. ncbi Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902
    J A van der Hage
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Clin Oncol 19:4224-37. 2001
    ....
  67. doi The new lung cancer staging system
    Frank C Detterbeck
    Thoracic Surgery, Yale University School of Medicine, New Haven, CT 06520 8062, USA
    Chest 136:260-71. 2009
    ..This article reviews the recommendations of the IASLC International Staging Committee for the definitions for the TNM descriptors and the stage grouping in the new non-small cell lung cancer staging system...
  68. doi Micrometastases or isolated tumor cells and the outcome of breast cancer
    Maaike de Boer
    Division of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands
    N Engl J Med 361:653-63. 2009
    ..The association of isolated tumor cells and micrometastases in regional lymph nodes with the clinical outcome of breast cancer is unclear...
  69. doi Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
    Carole Fakhry
    Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Natl Cancer Inst 100:261-9. 2008
    ....
  70. pmc Systemic treatment of colorectal cancer
    Brian M Wolpin
    Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 134:1296-310. 2008
    ....
  71. ncbi Hepatocellular carcinoma: current management and recent advances
    Wan Yee Lau
    Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
    Hepatobiliary Pancreat Dis Int 7:237-57. 2008
    ..This article aims to review the current management of HCC and its recent advances...
  72. doi [Update S3-guideline "colorectal cancer" 2008]
    W Schmiegel
    Verantwortliche Institution Leitliniensekretariat Medizinische Klinik, Knappschaftskrankenhaus, Ruhr Universität Bochum und die AWMF im Auftrag der DGVS und der DKG Koordinatoren und Mitglieder der Konferenz siehe Anlage 1 3
    Z Gastroenterol 46:799-840. 2008
  73. pmc Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
    Christopher M Nutting
    Head and Neck Unit, Royal Marsden Hospitals NHS Foundation Trust, London, UK
    Lancet Oncol 12:127-36. 2011
    ..Compared with conventional radiotherapy, intensity-modulated radiotherapy (IMRT) can reduce irradiation of the parotid glands. We assessed the hypothesis that parotid-sparing IMRT reduces the incidence of severe xerostomia...
  74. ncbi Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer
    B C H van der Wal
    Department of Surgery, St Lucas Andreas Hospital, Amsterdam, The Netherlands
    Eur J Surg Oncol 28:481-9. 2002
    ..This study investigated whether the total number of removed lymph nodes and the ratio of invaded/removed lymph nodes (lymph node ratio (LNR) would prove to be independent prognostic factors for survival...
  75. doi Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction
    Bernhard Mlecnik
    Inserm U872, Integrative Cancer Immunology Team, 15 rue de l Ecole de Medecine, Centre de Recherche des Cordeliers, 75006 Paris, France
    J Clin Oncol 29:610-8. 2011
    ....
  76. doi Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
    Alexandar Tzankov
    Department of Pathology, University Hospital Basel, Schoenbeinstr 40, CH 4031 Basel, Switzerland
    Haematologica 93:193-200. 2008
    ..The tumor microenvironment is important for the behavior of cancer. We assessed the distribution and biological significance of FOXP3(+) regulatory T-cells (Treg) in lymphomas...
  77. ncbi Gastric cancer treatment guidelines in Japan
    Toshifusa Nakajima
    Cancer Institute Hospital, 1 37 1 Kamiikebukuro, Toshima ku, Tokyo 170 8455, Japan
    Gastric Cancer 5:1-5. 2002
    ....
  78. doi Lymph node ratio: role in the staging of node-positive colon cancer
    Jiping Wang
    Department of Surgery, University at Buffalo, State University of New York, Buffalo, New York, USA
    Ann Surg Oncol 15:1600-8. 2008
    ..We hypothesize that LNR may play a similar role in stage III colon cancer...
  79. doi Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer
    David Schilling
    Department of Radiology, University Hospital Tubingen, Germany
    BJU Int 102:446-51. 2008
    ..To evaluate the potential of (11)C-choline-positron emission tomography (PET)/computed tomography (CT) for planning surgery in patients with prostate cancer and prostate-specific antigen (PSA) relapse after treatment with curative intent...
  80. doi Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases
    M G W Scheer
    Department of Surgery, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Ann Oncol 19:1829-35. 2008
    ..Resection of the primary tumor followed by chemotherapy when possible versus systemic chemotherapy followed by resection of the primary tumor when necessary are compared in this systematic review...
  81. doi Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer
    Guorong Li
    Department of Urology, North Hospital, CHU of Saint Etienne, Saint Etienne, France
    J Urol 180:510-3; discussion 513-4. 2008
    ..We explored the clinical usefulness of serum carbonic anhydrase 9 as a potential biomarker for conventional renal cell cancer...
  82. doi Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation
    Ann H Klopp
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 115:6-11. 2009
    ..To evaluate treatment outcomes and patterns of recurrence in patients with node-positive (International Federation of Obstetrics and Gynecology stage IIIC) adenocarcinoma of the uterus without serous or clear cell differentiation...
  83. pmc A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 16:5222-32. 2010
    ....
  84. doi Comprehensive miRNA profiling of surgically staged endometrial cancer
    David E Cohn
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA
    Am J Obstet Gynecol 202:656.e1-8. 2010
    ..We sought to determine a microRNA (miRNA) profile of surgically staged endometrial cancers...
  85. ncbi Survival rate of gastric and esophageal cancers in Ardabil province, North-West of Iran
    Fatemeh Samadi
    Digestive Disease Research Center DDRC, Tehran University of Medical Sciences, Tehran, Iran
    Arch Iran Med 10:32-7. 2007
    ..We conducted this study to determine the present survival rate of patients with esophageal and gastric cancers before launching interventional studies...
  86. ncbi Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
    Herve Bonnefoi
    Geneva University Hospital, Geneva, Switzerland
    Lancet Oncol 8:1071-8. 2007
    ..The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial...
  87. ncbi Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability
    Brian Lang
    Division of Endocrine Surgery, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China
    Ann Surg Oncol 14:1551-9. 2007
    ..The objective of the present study was to evaluate the potential changes in cancer-specific survival (CSS) after reclassification from fifth to sixth edition TNM...
  88. doi Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station?
    Hee Seok Lee
    Center for Lung Cancer, National Cancer Center, 809 Madu dong, Ilsan gu, Goyang, Gyeonggi, 411 764, Korea
    Chest 134:368-74. 2008
    ....
  89. doi Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens
    Peh Sun Loo
    Department of Pathology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland, UK
    J Thorac Oncol 5:442-7. 2010
    ..Histochemical staining for mucin and immunohistochemical (IHC) identification of NSCLC subtype-associated markers could help predict the final subtype of resected NSCLCs diagnosed as NSCLC-NOS on preoperative bronchial biopsy samples...
  90. pmc Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment
    George A Poultsides
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:3379-84. 2009
    ....
  91. pmc Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer
    K A Voutilainen
    Department of Pathology and Forensic Medicine, University of Kuopio and Kuopio University Hospital, Finland
    J Clin Pathol 59:460-7. 2006
    ..To clarify the prognostic role of E-cadherin and beta- and gamma-catenins, and their relation to CD44 in epithelial ovarian carcinoma...
  92. ncbi Positron-emission tomography and assessment of cancer therapy
    Malik E Juweid
    Department of Radiology and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City 52242, USA
    N Engl J Med 354:496-507. 2006
  93. ncbi Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification
    Lars Dyrskjøt
    Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Aarhus N, Denmark
    Cancer Res 64:4040-8. 2004
    ..Identification of this expression signature could provide guidance for the selection of therapy and follow-up regimen in patients with early stage bladder cancer...
  94. ncbi Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET
    Igle J de Jong
    Department of Urology and PET Center, Groningen University Hospital, Groningen, The Netherlands
    J Nucl Med 44:331-5. 2003
    ..The aim of this study was to evaluate the strength and accuracy of (11)C-choline PET in preoperative noninvasive staging of pelvic lymph nodes in prostate cancer...
  95. ncbi Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma
    Fabrice Denis
    Clinique d Oncologie et Radiothérapie, Hopital Bretonneau, 2 Blvd Tonnelé, 37044 Tours, France
    J Clin Oncol 22:69-76. 2004
    ....
  96. pmc Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer
    G Scambia
    Department of Gynecology and Obstetrics, Catholic University, Rome, Italy
    Br J Cancer 71:354-6. 1995
    ..0009). Multivariate analysis revealed that IL-6 positivity has an independent value...
  97. ncbi Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends
    Shotaro Nakamura
    Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Cancer 97:2462-73. 2003
    ..This study aimed to elucidate the clinicopathologic features of this disease and the influence of therapeutic modalities on the prognosis in Japanese patients..
  98. ncbi Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination
    P Jestin
    The Department of Surgical Sciences, Akademiska sjukhuset, Colorectal Unit, Uppsala University, SE 751 85, Uppsala, Sweden
    Eur J Cancer 41:2071-8. 2005
    ..An index of metastases (IM) is a possible basis for guidance in the choice of adjuvant treatments that appears superior to that of N-stage...
  99. ncbi Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients
    G Ferrandina
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    Ann Oncol 13:1205-11. 2002
    ..The aim of this study was to investigate the expression of COX-2 and its association with clinicopathological parameters, response to treatment, and clinical outcome in ovarian cancer patients...
  100. ncbi Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer
    Claus Rodel
    Department of Radiation Therapy, University of Erlangen, Universitatsstr 27, D 91054 Erlangen, Germany
    J Clin Oncol 23:8688-96. 2005
    ..We assessed the impact of tumor regression grading (TRG) and its value in correlation to established prognostic factors in a cohort of rectal carcinoma patients treated by preoperative chemoradiotherapy (CRT)...
  101. ncbi The degree and time-course assessment of radiation-induced trismus occurring after radiotherapy for nasopharyngeal cancer
    Chon Jong Wang
    Department of Radiation Oncology, Kaoshiung Chang Gung Memorial Hospital, 123 Ta Pei Road, Niao Sung Hsiang, Kaohsiung Hsien 833, Taiwan
    Laryngoscope 115:1458-60. 2005
    ..The objectives were to measure the degree of trismus induced after radiation therapy for nasopharyngeal cancer and assess its progress over time...

Research Grants224 found, 100 shown here

  1. REGULATION OF PROSTATE CANCER PROGRAMMED CELL DEATH
    Andrew Kraft; Fiscal Year: 2001
    ..Information gained from these studies will provide the background and animal models to examine MKP-1 or regulation of apoptosis as a target for antiprostate cancer therapy. ..
  2. A Genetic Screening Policy Model for Colorectal Cancer
    Scott Ramsey; Fiscal Year: 2006
    ..The model will incorporate QOL information from Aim 2, along with family history, clinical, and screening information from the Seattle CFR. ..
  3. Clinical Significance of Apoptosis in Colon Cancer
    Frank Sinicrope; Fiscal Year: 2006
    ..abstract_text> ..
  4. Aberrant Crypt Foci as a Biomarker for Chemoprevention
    Frank Sinicrope; Fiscal Year: 2009
    ....
  5. Aberrant Crypt Foci as a Biomarker for Chemoprevention
    Frank Sinicrope; Fiscal Year: 2007
    ....
  6. A Novel Breast Cancer Biomarker
    Dennis Sgroi; Fiscal Year: 2009
    ..abstract_text> ..
  7. Polyphenon E for the Chemoprevention of Colorectal Cancer
    Frank A Sinicrope; Fiscal Year: 2010
    ..We will determine the effect of polyphenon E on precursor lesions of colorectal adenomas in patients at high risk of colorectal cancer. ..
  8. A Novel Breast Cancer Biomarker
    Dennis C Sgroi; Fiscal Year: 2010
    ....
  9. Timing of Rectal Cancer Response to Chemoradiation
    Julio Garcia Aguilar; Fiscal Year: 2009
    ..This information will help develop molecular assays to diagnose pathologic complete response in transrectal biopsies of the tumor bed before removing the rectum. ..
  10. Mechanisms of Carcinogenesis in Biliary Epithelia
    Gregory Gores; Fiscal Year: 2005
    ..Successful completion of these proposed studies has the potential for development of new strategies to prevent and treat malignant human liver diseases. ..
  11. Regulation of the von Hippel-Lindau Protein
    Paul Corn; Fiscal Year: 2007
    ..abstract_text> ..
  12. Morphine versus Methadone as First Line Strong Opioid for Cancer Pain
    Eduardo Bruera; Fiscal Year: 2007
    ..Relevance to Public Health: In this study, we will test if methadone is better than morphine in cancer pain control, quality of life, and is more cost-effective. ..
  13. HOME BASED MODERATE EXERCISE FOR BREAST CANCER PATIENTS
    Bernardine Pinto; Fiscal Year: 2002
    ..This study also raises the intriguing possibility of elucidating the physiological effects of exercise on hormonal and immune mechanisms involved in breast cancer. ..
  14. Tumor microenvironment, tissue liquidity, and cell interaction in prostate cancer
    Ramsey A Foty; Fiscal Year: 2010
    ..These forces impart to tumors mechanical properties that can be measured and correlated with invasiveness. This proposal explores how these forces and the molecules giving rise to them contribute to invasiveness. ..
  15. Inflammatory Biomarkers and Colorectal Cancer Risk
    Gong Yang; Fiscal Year: 2010
    ..Overall, this study will contribute significantly to the understanding of the role of inflammation in the etiology of CRC and to the development of new strategies for the assessment of CRC risk. ..
  16. Promoting Physical Activity after Colorectal Cancer
    Bernardine Pinto; Fiscal Year: 2006
    ..abstract_text> ..
  17. Methylphenidate for Fatigue in Advanced Cancer Patients
    Eduardo Bruera; Fiscal Year: 2009
    ....
  18. Acupuncture to aid post-colectomy recovery in colorectal cancer patients
    Gary Deng; Fiscal Year: 2007
    ....
  19. Reflexology: An Intervention for Advanced Breast Cancer
    Gwen Wyatt; Fiscal Year: 2009
    ..Finally, this study utilizes an improved design over existing work. It is a RCT with adequate numbers to detect group differences, and could ultimately serve as a model for rigorous investigation of other complementary therapies. ..
  20. Inflammatory Biomarkers and Colorectal Cancer Risk
    Gong Yang; Fiscal Year: 2007
    ..Overall, this study will contribute significantly to the understanding of the role of inflammation in the etiology of CRC and to the development of new strategies for the assessment of CRC risk. ..
  21. Tools for Economic Analysis of Patient Management Interventions in Heart Failure
    Shelby Reed; Fiscal Year: 2009
    ..The TEAM-HF projects will provide clinicians and researchers with user-friendly tools to facilitate the conduct of high-quality economic evaluations of patient-focused interventions. ..
  22. Prostate cancer and genes of the one-carbon cycle
    Charnita Zeigler Johnson; Fiscal Year: 2006
    ....
  23. Bispecific Antibody Engineering for AML RIT
    OLIVER W contact PRESS; Fiscal Year: 2010
    ..We anticipate that this approach will cure more patients and cause fewer toxicities than currently available therapies. ..
  24. MECHANISMS OF LIVER CELL INJURY
    Gregory J Gores; Fiscal Year: 2010
    ..The results of these studies are germane to mechanisms of liver injury in the common syndrome of nonalcoholic fatty liver disease, and have the potential to identify new therapeutic strategies for this liver disease. ..
  25. Molecular Detection of Occult Neuroblastoma
    Irene Cheung; Fiscal Year: 2004
    ..If these two molecular markers of MRD can independently predict patient outcome, they will in the future provide an objective endpoint for stopping further treatment, and serve as sensitive surrogates for evaluating adjuvant therapies. ..
  26. Iyengar Yoga for Breast Cancer Survivors with Persistent Fatigue
    Julienne Bower; Fiscal Year: 2007
    ..The development of targeted treatments for cancer-related fatigue is critical for maintaining quality of life in the growing population of breast cancer survivors. ..
  27. Parenteral Hydration in Advanced Cancer Patients: A Randomized Controlled Trial
    Eduardo Bruera; Fiscal Year: 2009
    ..In this study, we will test if giving fluid through the vein will improve the symptoms, delay confusion and prolong life in patients who are no longer to drink at the end of life. ..
  28. MECHANISMS OF LIVER CELL INJURY
    Gregory J Gores; Fiscal Year: 2010
    ..The results of these studies are germane to mechanisms of liver injury in the common syndrome of nonalcoholic fatty liver disease, and have the potential to identify new therapeutic strategies for this liver disease. ..
  29. Control of Eye Melanoma Metastasis
    Hans Grossniklaus; Fiscal Year: 2007
    ..The third aim determines the mechanism of combined angiostatin/IFN control of the micrometastases using methods in the first two aims. ..
  30. Fiber and Colorectal Adenomas: A Pooling Project
    Elizabeth Jacobs; Fiscal Year: 2005
    ..If it is found that certain groups may receive greater benefit from fiber, then public health recommendations can be made which target these groups and prevent the recurrence of colorectal adenomas. ..
  31. CLASSIFYING PANCREATIC CANCERS BY METHYLATOR PHENOTYPES
    Michael Goggins; Fiscal Year: 2006
    ..Aim #4: Determine if functional DNA methylation differences exist between CIMP+ compared to CIMP- pancreatic carcinomas. ..
  32. Cancer Control Research Training in Multiethnic Hawaii
    Gertraud Maskarinec; Fiscal Year: 2007
    ..This training environment, together with the proposed Program plan, provides an ideal opportunity for quality career development for cancer control scientists in the twenty-first century. ..
  33. Mechanisms by which Proteasome Enhance Apoptosis
    Andrew Kraft; Fiscal Year: 2007
    ..abstract_text> ..
  34. FOLATE PATHWAY POLYMORPHISMS AND PANCREATIC CANCER RISK
    Michael Goggins; Fiscal Year: 2002
    ..abstract_text> ..
  35. Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
    Craig Slingluff; Fiscal Year: 2007
    ....
  36. Breast and Prostate Cancer Patterns of Care
    Rosemary Cress; Fiscal Year: 2007
    ..What is learned about treatment quality and completeness can subsequently be used to improve the information in these registries so that they can become a resource for researchers evaluating quality of cancer care. ..
  37. Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab
    Craig Slingluff; Fiscal Year: 2007
    ..The following proposal is a clinical trial to evaluate the effects of bevacizumab and CCI-779, which interfere with vascularization and tumor growth, for the treatment of melanoma. ..
  38. FDG PET-CT in Metastatic Prostate Cancer
    Hossein Jadvar; Fiscal Year: 2007
    ..Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting. ..
  39. Real-time Minimal Residual Disease assay of Pediatric B-Cell Non-Hodgkin Lymphoma
    Bruce Shiramizu; Fiscal Year: 2007
    ..The assay developed by this exploratory proposal could be incorporated into pediatric B-cell NHL studies to assess MRD on therapy or to assess the efficacy of innovative therapies. ..
  40. A Pharmacogenetic approach to prostate cancer susceptibility
    LA CREIS KIDD; Fiscal Year: 2007
    ....
  41. Markers of Genetic Susceptibility to Bladder Cancer
    Xifeng Wu; Fiscal Year: 2007
    ..The ability to rapidly screen individuals for risk, using minimally invasive procedures (blood samples), has immense clinical implication, such as intensive screening and chemopreventive interventions. ..
  42. The Gulf Coast MBCCOP
    Paul Schwarzenberger; Fiscal Year: 2007
    ..We propose to expand on this in collaboration with Dr. Conrad who will serve so- a consultant nn thic nrnnneal ..
  43. OCULAR MELANOMA
    Paul Finger; Fiscal Year: 2003
    ..Standardized clinical and data collection procedures will be employed, and standardized forms will be used in all centers. Central training and certification of all study staff will be required. ..
  44. Genetic Instability & Risk for Esophageal Carcinoma
    Xifeng Wu; Fiscal Year: 2010
    ..The ability to rapidly screen individuals for risk, using minimally invasive procedures (blood samples), has immense clinical implication, such as intensive screening and chemopreventive interventions. ..